BPG is committed to discovery and dissemination of knowledge
Translational Research
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 125917
Published online Nov 24, 2026. doi: 10.5306/wjco.125917
Figure 1
Figure 1 Spatial transcriptomics reveals distinct regions enriched for M1-like and M2-like signatures and their clinical relevance in colorectal cancer. A: Spatial feature plots showing AUCell-based M1-like and M2-like macrophage-associated transcriptional-program scores across a conventional 10x Genomics Visium FFPE colorectal cancer (CRC) specimen from tissue block 1281585B, slide V10L13-021, capture area B1. Each point represents one spatial spot rather than an individual cell; B: Comparison of mean AUCell signature scores for the M1-like and M2-like macrophage-associated transcriptional programs across malignant, mixed, and normal regions of specimen CRC2; P values for regional comparisons are shown. AUCell scores represent gene-set activity and are distinct from receiver-operating-characteristic area under the curve (AUC); C: Correlation-based spatial association matrix and network visualization illustrating the association between macrophage signature activity (AUC) and inferred abundances of major tumor microenvironment cell types (e.g., CD4⁺ T cells, CD8⁺ T cells, NK cells, B cells, plasma cells, macrophages, DCs, neutrophils, endothelial cells, fibroblasts, epithelial cells, and tumor cells). The colors indicate positive/negative correlations, and the line thickness reflects the correlation strength; D: Violin/box plots of single-sample gene set enrichment analysis (ssGSEA) scores for M1 and M2 signatures in early-stage (I–II) vs advanced-stage (III-IV) CRC; E: Kaplan–Meier analysis of overall survival stratified by high vs low M1 or M2 ssGSEA scores; group sizes and log-rank P values are indicated. CRC: Colorectal cancer; ssGSEA: Single-sample gene set enrichment analysis; TME: Tumor microenvironment.
Figure 2
Figure 2 Construction and evaluation of an M1-related prognostic model using LASSO-Cox and multialgorithm machine learning. A: Tenfold cross-validation curve for LASSO Cox regression showing model deviance across log(λ), with the number of retained features indicated; B: LASSO coefficient profiles of candidate genes across log(λ); dashed vertical lines denote the selected λ values; C: Differential expression analysis of M1-like TAM-associated candidate genes between colorectal cancer tissues and normal tissues; D: Comparison of prognostic-model performance across 14 dataset-endpoint combinations using the mean of the 1-, 3-, and 5-year time-dependent area under the curve (AUC) values. The evaluated algorithms included backward, forward, and bidirectional stepwise Cox regression, CoxBoost, ridge Cox, elastic-net Cox, and LASSO-Cox. Because the endpoint definitions differed across datasets, each dataset-endpoint combination was evaluated separately. The complete AUC values are provided in Supplementary Table 5; E: Distribution of regression coefficients of candidate genes across multiple survival-learning models. bP < 0.01; dP < 0.0001. AUC: Area under the curve.
Figure 3
Figure 3 Exploratory Human Protein Atlas staining differences and cohort-specific prognostic associations of NFKB1 expression in colorectal cancer. A: Representative NFKB1 immunohistochemistry images retrieved from the Human Protein Atlas using antibody HPA027305. Three colorectal cancer specimens and three normal colon specimens from different patients are shown. The corresponding Human Protein Atlas record identifiers, patient characteristics, pathological annotations, staining intensity, staining quantity, staining location, and image names are provided in Supplementary Table 2; B: Exploratory semiquantitative comparisons of the 3,3′-Diaminobenzidine (DAB) positive area percentage, mean DAB optical density, and integrated DAB optical density between normal colon and colorectal cancer specimens. Three nonoverlapping regions of interest were evaluated per image, and their mean was used as the independent patient-level value. Each point represents one patient specimen (n = 3 per group). Comparisons were performed using two-sided Welch’s t-tests; C: Forest plot of univariable and multivariable Cox regression analyses evaluating the prognostic impact of NFKB1 together with clinicopathological variables (e.g., age, sex, stage/T/N/M) in The Cancer Genome Atlas and independent Gene Expression Omnibus validation cohorts; D: Exploratory Kaplan–Meier curves stratified by cohort-specific median NFKB1 expression. Relapse-free survival was analyzed in GSE17537, whereas overall survival was analyzed in GSE29621, GSE71187, and GSE72970. Group sizes and log-rank P values are shown. Median dichotomization was used for visualization and does not represent a clinically validated cutoff. aP < 0.05; bP < 0.01; TCGA: The Cancer Genome Atlas; HR: Hazard ratio. DAB: 3,3′-Diaminobenzidine.
Figure 4
Figure 4 Immune-related transcriptional features, KEGG-GSEA patterns, and computationally predicted drug-response associations according to NFKB1 expression. A: Heatmaps of differential immune-related molecules between NFKB1-low and NFKB1-high tumors, including immunostimulators, chemokines, and immunoinhibitors; significance is indicated by superscript lowercase letters; B: Distribution comparisons of immune activation signatures between groups, including the T-cell–inflamed score, tertiary lymphoid structure signature, interferon-γ signature, and cytolytic activity, are shown as density plots with embedded box plots and P values; C: KEGG gene set enrichment analysis comparing the highest 30% and lowest 30% of TCGA-CRC samples ranked by NFKB1 expression. All genes were ranked according to the limma-derived log2 fold change. Positive normalized enrichment scores indicate relative enrichment in the NFKB1-high group, whereas negative scores indicate relative enrichment in the NFKB1-low group. Benjamini-Hochberg-adjusted P values were used to control the false discovery rate (FDR). Complete results are provided in Supplementary Table 7; D: Predicted drug sensitivity and mechanism-of-action mapping based on the pharmacogenomic resource Genomics of Drug Sensitivity in Cancer. Candidate compounds associated with subgroup-specific vulnerability are linked to their putative target pathways; edges represent drug–pathway associations. All available GDSC1 and GDSC2 compound–NFKB1 correlation coefficients and nominal P values from the original significant-result exports are provided in Supplementary Table 8. The source exports did not retain an FDR-adjusted P value column. These results are computational associations and do not represent observed clinical responses. aP < 0.05; bP < 0.01; cP < 0.001. TLS: Tertiary lymphoid structure; IFN-γ: Interferon-γ; CYT: Cytolytic.


Write to the Help Desk